Genomic Health Uses Tecan Workstations to Automate Cancer Assay Development

Aug 08, 2007

NEW YORK (GenomeWeb News) - Genomic Health is using Tecan’s liquid-handling workstations to automate the developmental process for its cancer recurrence assays, Tecan said this week.

Genomic Health markets Oncotype DX, a gene expression assay that predicts the risk of recurrence of cancer and the likelihood of chemotherapy benefit in early-stage breast cancer patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

Mosquito Population Crash

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Main menu